Preparation of Sustained Release Tablet with Minimized Usage of Glyceryl Behenate Using Post-Heating Method
The purpose of this study was to prepare sustained release (SR) matrix tablets using a direct compression incorporated with a post-heating process. Allopurinol was selected due to the water-soluble property and Compritol 888 ATO® (also known as glyceryl behenate) was used as an SR matrix-forming agent. The API, SR material, microcrystalline cellulose, and magnesium stearate (lubricant) were mixed and prepared into a tablet by a direct compression method. The compressed tablets were stored in a dry oven at four temperatures (60, 70, 80, and 90°C) and for three time periods (15, 30, 45 min). The DSC and PXRD data indicated that the crystallinity of the API was not altered by the post-heating method. However, SEM images demonstrated that Compritol 888 ATO® was melted by the post-heating method, and that the melted Compritol 888 ATO® could form a strong matrix. This strong matrix led to the significant sustained release behavior of hydrophilic APIs. As little as 3 mg of Compritol 888 ATO® (0.65% of total tablet weight), when heated at 80°C for 15 min, showed sustained release over 10 h. The post-heating method exerted a significant influence on lipid-based matrix tablets and allowed a reduction in the amount of material required for a water-soluble drug. This will also provide a valuable insight into lipid-based SR tablets and will allow their application to higher quality products and easier processing procedures.
KEY WORDSpost-heating glyceryl behenate sustained release direct compression dry oven
This work was supported by the Sahmyook University Research Fund in 2016 (no. RI22016007).
Compliance with Ethical Standards
Conflict of Interest
The authors declare that there is no conflict of interests regarding the publication of this paper.
- 14.Smith, A., Datta, S.P., Smith, G.H., Campbell, P.N., Bentley, R., McKenzie, H. Oxford dictionary of biochemistry and molecular biology, 2nd ed. Oxford: Oxford University Press; 2000.Google Scholar
- 15.Weiner, A. Lipid excipient for nasal delivery and topical application. US5200393A; 1993.Google Scholar
- 23.Food and Drug Administration, Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Food and Drug Administration, Rockville, MD. 2000.Google Scholar